Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Corcept Therapeutics Incorporated common stock during the specified Class Period, indicating potential legal issues surrounding the company's New Drug Application for relacorilant [1][5]. Group 1: Lawsuit Details - The class action lawsuit is focused on the period between October 31, 2024, and December 30, 2025, during which Corcept allegedly misrepresented the status of its NDA for relacorilant, claiming strong support from clinical trials while the FDA had raised concerns about the evidence [1][5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees, as compensation may be available through a contingency fee arrangement [2]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including a notable $438 million secured for investors in 2019 [4]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the firm directly for more information [3][6]. - It is noted that no class has been certified yet, and investors have the option to select their counsel or remain absent from the class at this stage [7].

LOS ANGELES, Feb. 27, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to fcruz@frankcruzlaw.com. Kyndr ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Corcept Therapeutics Incorporated common stock during the specified Class Period, indicating potential legal recourse for affected investors [1]. Group 1: Class Action Details - The class action lawsuit is for purchasers of Corcept common stock between October 31, 2024, and December 30, 2025, inclusive [1]. - Investors who purchased shares during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company and has recovered hundreds of millions for investors [4]. Group 3: Case Background - The lawsuit alleges that Corcept misrepresented the status of its New Drug Application (NDA) for relacorilant, claiming strong support from clinical trials while the FDA had raised concerns about the evidence [5]. - Defendants reportedly assured investors that there were no impediments to NDA approval, despite known risks that it might not be approved [5].

Robbins LLP Urges TCPC Investors With Larges Losses in BlackRock TCP Capital Corp. to Contact the Firm for Information About the Class Action Lawsuit[Accessibility Statement] [Skip Navigation]SAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- [Robbins LLP] reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired BlackRock TCP Capital Corp. (NASDAQ: [TCPC]) securities between November 6, 2024 and January 23, 2026. BlackRock TCP is a business development company ...

company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. For more information, submi...## ARDT Class Action Reminder: Stockholders Who Lost Money Investing in Ardent Health, Inc. Should Contact Robbins LLP for Information About Recovering Their LossesSAN DIEGO--([BUSINESS WIRE])--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or ot ...

GRAL INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into GRAIL, Inc., Encourages Investors and Potential Witnesses to Contact Law Firm [Accessibility Statement] Skip NavigationSAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- The law firm of [Robbins Geller Rudman & Dowd LLP] is investigating potential violations of U.S. federal securities laws involving GRAIL, Inc. (NASDAQ: GRAL).If you have information that could assist in the GRAIL investigation or if you are a GRAIL investor who su ...

Polen Capital, an investment management company, released its fourth-quarter investor letter for “Polen 5Perspectives Small Growth Strategy”. A copy of the letter can be downloaded here. The Polen 5Perspectives Small Growth Composite Portfolio returned -1.3% gross and -1.5% net of fees in the fourth quarter of 2025, compared to a 1.2% return of the Russell 2000 Growth Index. Following double-digit returns in 2Q and 3Q, small caps concluded the year with a 1.2% return in 4Q. Biotech stood out as a major per ...

Core Viewpoint - Kahn Swick & Foti, LLC is investigating the proposed sale of Arcellx, Inc. to Gilead Sciences, Inc. to assess the adequacy of the price and process involved in the transaction [1] Group 1: Proposed Transaction Details - Under the terms of the proposed sale, shareholders of Arcellx will receive $115.00 per share in cash, along with one contingent value right of $5.00 per share contingent on achieving certain milestones [1] - The investigation aims to determine whether the proposed consideration undervalues Arcellx and if the process leading to this valuation was adequate [1] Group 2: Legal Rights and Actions - Shareholders who believe the transaction undervalues the company are encouraged to discuss their legal rights with Kahn Swick & Foti, LLC [1] - The transaction is structured as a tender offer, indicating that timing may be critical for shareholders [1]

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Corcept Therapeutics Incorporated ("Corcept†or the "Company†) (NASDAQ:CORT) securities during the period of October 31, 2024 through December 30, 2025, inclusive ("the Class Period†). If you suffered a loss on your Corcept investments, you have until April 21, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff app. ...

The S&P 500 (SNPINDEX:^GSPC) fell 0.28% to 6,861.89, breaking a three-day winning streak. Geopolitical tensions and weaker confidence weighed on the Nasdaq Composite (NASDAQINDEX:^IXIC), which slipped 0.31% to 22,682.73, and the Dow Jones Industrial Average (DJINDICES:^DJI), which dropped 0.54% to 49,395.16. Market movers Walmart (NASDAQ:WMT) fell after issuing weaker-than-expected guidance. This put pressure on Dow futures and retail peers. DoorDash (NASDAQ:DASH) and Medical Properties Trust (NYSE:MPT) ...